Inhibition of γδT cells using an anti‐γδTCR mAb in aged mice significantly reduced the mean survival time from 48.63 to 34.38 days after the B16/F10 melanoma challenge, but not the depletion of CD4+T cells by anti‐CD4 mAb treatment (Figure 5d). This evidence concerns the gene CD4 and melanoma.